Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
About the study
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- No evidence of extrahepatic disease
- Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
- Child Pugh score class A
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
- Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
- Adequate organ and marrow function
EXCLUSION CRITERIA
Exclusion Criteria:
- History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
- History of hepatic encephalopathy
- Major portal vein thrombosis visible on baseline imaging
- Uncontrolled arterial hypertension
- Co-infection with HBV and HDV
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hepatocellular Carcinoma
Age (in years)
18 - 120
Phase
Phase 3
Participants needed
725
Est. Completion Date
Feb 26, 2027
Treatment type
Interventional
Sponsor
AstraZeneca
ClinicalTrials.gov identifier
NCT05301842
Study number
D910VC00001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?